arrow
A

Aleksandra Markovets

merck & company
H指数:21
被引数:2,622

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
2024-04-054
PRE
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

EGFR突变的晚期非小细胞肺癌对一线奥希替尼获得性耐药的候选机制

2023-02-2772
OAAI
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

EGFR抑制剂osimertinib药物耐受性持久细胞的治疗脆弱性

2022-12-2713
OAAI
Osimertinib plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON

Osimertinib联合Savolitinib克服表皮生长因子受体突变、MET扩增非小细胞肺癌获得性MET介导的耐药: TATTON

2022-10-2070
OAAI
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer

来自AURA3试验的组织和血浆中的表皮生长因子受体突变分析: 奥希替尼与铂类培美曲塞治疗T790M突变阳性的晚期非小细胞肺癌

CANCER
IF5.1
2019-11-2697
OAAI